TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02236988

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Immediate Release
Description: 30 mg immediate release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Immediate Release
Description: 30 mg immediate release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Immediate Release
Description: 30 mg immediate release tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 1
Description: 75 mg oral tablet of prototype modified release (MR) 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 2
Description: 75 mg oral tablet of prototype MR 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 3
Description: 75 mg oral capsule of prototype MR 3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 4
Description: 75 mg oral capsule of prototype MR 4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 5
Description: 75 mg oral capsule of prototype MR 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 6
Description: 75 mg oral capsule of prototype MR 6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 8
Description: 80 mg oral capsule of prototype MR 8

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 9
Description: 80 mg oral capsule of prototype MR 9

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 11
Description: 80 mg oral capsule of prototype MR 11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 12
Description: 80 mg oral capsule of prototype MR 12

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 13
Description: 80 mg oral capsule of prototype MR 13

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Modified Release 14
Description: 80 mg oral capsule of prototype MR 14
Study: NCT02448433

Intervention type: DEVICE
Group type: OTHER
Intervention: Phototherapy light-emitting glasses
Description: The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m\^2) upon awakening and progressive shift to earlier wake-up times.~Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.~During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls.
Study: NCT00692731

Intervention type: DIETARY_SUPPLEMENT
Intervention: 500 mL/day of a beverage providing approximately 625 mg catechins
Description: Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins

Intervention type: OTHER
Intervention: Control beverage matched for energy and caffeine content
Description: 500 mL/day of a control beverage
Study: NCT04057027

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Description: During the C section, infants' umbilical cord clamping will be delayed for 30-60 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed umbilical cord clamping
Description: During the C section, infants' umbilical cord clamping will be delayed for 30-60 seconds.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cord Milking
Description: Umbilical cord will be milked from th distance of 20cm from mother's side to the baby, for 3-4 times.
Study: NCT01994967

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine
Description: Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
Study: NCT02966808

Intervention type: BEHAVIORAL
Intervention: cognitive and behavioural questionnaires
Study: NCT04548466

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEP bottle
Study: NCT03499470

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Protocol for structured discharge and follow-up
Study: NCT00960453

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods

Intervention type: DRUG
Group type: OTHER
Intervention: Sitagliptin
Description: Dosage form: 25mg, 50mg ,100mg~Amount: 25mg, 50mg, 100mg~Frequency and duration: once a day, for 4 days, including 5 days washout periods
Study: NCT02826343

Intervention type: DRUG
Group type: OTHER
Intervention: Xenon129 MRI imaging
Description: subjects will receive at baseline and 3 month post Advair intervention (See next intervention)

Intervention type: DRUG
Group type: OTHER
Intervention: Gadolinium MRI
Description: subjects will receive at baseline and 3 month post Advair intervention (See next intervention)

Intervention type: DRUG
Group type: OTHER
Intervention: Advair (250mcg/50mcg) one puff twice a day
Description: subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
Study: NCT03788759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha-lipoic acid
Description: Administration of ALA (100 mg/day) for 4 months, as an adjunct to antipsychotic medication.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Administration of placebo, as an adjunct to antipsychotic medication.
Study: NCT03674580

Intervention type: BEHAVIORAL
Intervention: Follow-up of the suicidal patients
Description: No intervention. Follow-up of the suicidal patients
Study: NCT00650884

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: Ankle Dorsiflexion Dynasplint System
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ankle Dorsiflexion Dynasplint System
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.

Intervention type: DEVICE
Group type: OTHER
Intervention: Ankle Dorsiflexion Dynasplint System
Description: Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
Study: NCT03395262

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active with caffeine
Description: Novel formula with caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Active without caffeine
Description: Novel formula without caffeine

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dextrose placebo
Study: NCT03553199

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TRS, Tissue Retraction System
Description: Tissue Retraction System
Study: NCT00956553

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cervarix
Description: Three doses of Cervarix at month 0, 1 and 6.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Gardasil
Description: Three doses of Gardasil at month 0, 1 and 6.
Study: NCT01145209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ofatumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study: NCT00124683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine transdermal patch

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: nicotine transdermal patch
Study: NCT01035645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1070806
Description: The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.~Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation.
Study: NCT02360033

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Systemic Therapy for Social Anxiety Disorder

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Social Anxiety Disorder
Study: NCT00910039

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cognitive assessment
Description: The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
Study: NCT01481987

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Epiretinal Membrane Surgical treatment
Description: epiretinal membrane peeling
Study: NCT02550353

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lenticule extraction
Description: Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: femtosecond laser-assisted laser in situ keratomileusis
Description: track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
Study: NCT01143870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Report Card
Description: Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade.

Intervention type: OTHER
Group type: OTHER
Intervention: Diabetes Report Card
Description: Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diabetes Report Card
Description: Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade.
Study: NCT02627417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapsone (Disulone®)
Description: Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone (Cortancyl®) alone followed by monitoring and standard of care
Description: Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone (Cortancyl®)
Description: Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
Study: NCT01244529

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A Plus
Description: galyfilcon A Plus, BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A Plus
Description: galyfilcon A Plus, BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A Plus
Description: galyfilcon A Plus, BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A Plus
Description: galyfilcon A Plus, BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A Plus
Description: galyfilcon A Plus, BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A Plus
Description: galyfilcon A Plus, BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: seno A
Description: senofilcon A, BC:8.4 or 8.8

Intervention type: DEVICE
Group type: OTHER
Intervention: seno A
Description: senofilcon A, BC:8.4 or 8.8

Intervention type: DEVICE
Group type: OTHER
Intervention: seno A
Description: senofilcon A, BC:8.4 or 8.8

Intervention type: DEVICE
Group type: OTHER
Intervention: seno A
Description: senofilcon A, BC:8.4 or 8.8

Intervention type: DEVICE
Group type: OTHER
Intervention: seno A
Description: senofilcon A, BC:8.4 or 8.8

Intervention type: DEVICE
Group type: OTHER
Intervention: seno A
Description: senofilcon A, BC:8.4 or 8.8

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A
Description: galyfilcon A , BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A
Description: galyfilcon A , BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A
Description: galyfilcon A , BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A
Description: galyfilcon A , BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A
Description: galyfilcon A , BC: 8.3 or 8.7

Intervention type: DEVICE
Group type: OTHER
Intervention: galy A
Description: galyfilcon A , BC: 8.3 or 8.7
Study: NCT04076787

Intervention type: DRUG
Intervention: Sunitinib
Description: patients who received sunitinib as first line therapy for mRCC

Intervention type: DRUG
Intervention: Sunitinib
Description: patients who received sunitinib as first line therapy for mRCC

Intervention type: DRUG
Intervention: Sunitinib
Description: patients who received sunitinib as first line therapy for mRCC
Study: NCT01737424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LC28-0126
Description: LC28-0126

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00969826

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCPGC, Neulasta, Placebo
Description: A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCPGC, Neulasta, Placebo
Description: A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCPGC, Neulasta, Placebo
Description: A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GCPGC, Neulasta, Placebo
Description: A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
Study: NCT01066429

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Dexamethasone and dose-dense immunochemoterapy
Description: Administration every 14 days of the EDOCH-R scheme.
Study: NCT03446326

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacing
Description: Assess the non-invasively determined stroke volume and cardiac output response at different paced heart rates in patients with a cardiac pacemaker or implanted defibrillator with preserved ejection fractions (LVEF≥50%)
Study: NCT03846180

Intervention type: DRUG
Intervention: Terlipressin
Description: Continuous or intermittent intravenous infusion of terlipressin was given.

Intervention type: DRUG
Intervention: Somatostatin
Description: Continuous or intermittent intravenous infusion of somatostatin was given.

Intervention type: DRUG
Intervention: Octreotide
Description: Continuous or intermittent intravenous infusion of octreotide was given.
Study: NCT03859245

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: Photobiomodulation therapy, via Joovv red light/infrared LED device, three days/week, 20 minutes per session for experimental and control groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: Photobiomodulation therapy, via Joovv red light/infrared LED device, three days/week, 20 minutes per session for experimental and control groups.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Experimental group will follow a clinically prescribed ketogenic diet.
Study: NCT04984447

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TNIB Catheter
Description: Subjects will be asked to fast for 8 hours prior to study procedure and no liquids 2 hours prior to study procedure. Lidocaine jelly will may be used to help insert the TNIB Catheter through the Nares. Once inserted past the pharynx, imaging will begin. We will attempt to image the duodenum within 3 hours of study procedure starting.
Study: NCT02231073

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise and Education for Parkinson's Disease
Description: Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Education for Parkinson's Disease
Description: Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
Study: NCT04668430

Intervention type: OTHER
Group type: OTHER
Intervention: imaging and motion analysis
Description: performing a set of imaging and motion analysis tests before and after orthopedic surgery without modifying the operative indication or the pre- and post-operative management.
Study: NCT02472990

Intervention type: OTHER
Group type: OTHER
Intervention: No drug and no placebo were used in this study
Description: measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI

Intervention type: OTHER
Group type: OTHER
Intervention: No drug and no placebo were used in this study
Description: measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
Study: NCT00768170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0633
Description: MK0633 (50 mg) Oral, single dose
Study: NCT05635942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: optimized quadruple therapy
Description: Association of amoxicillin 3 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: standard quadruple therapy
Description: Association of amoxicillin 2 g/day + Esomeprazole, nitroimidazole and clarithromycin for 14 days
Study: NCT03952052

Intervention type: OTHER
Group type: OTHER
Intervention: Determination of mutation
Description: Recurrent mutation determination by digital PCR and next generation sequencing
Study: NCT03474926

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Routine Template-based lymphadenectomy
Description: Template-based LND was carried out in all patients in this group. The anatomical extent of LND is described in previous study. Lymph node specimens were sampled en bloc with surrounding adipose tissue, and were sent to pathological examination as individual packets with the surrounding adipose tissue.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LND only for lymph nodes enlargement found in preoperative image or during surgery
Description: LND was carried out only in patients who have lymph nodes enlargement in preoperative imaging (e.g. CTU or enhanced MRI) or who were found lymph nodes enlargement during surgery
Study: NCT02395029

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)